Skip to Content

'
Gunar K. Zagars, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1971 University of Sydney School of Medicine, Sydney, Australia, Bachelor of Surgery, Honors II, Surgery
1971 University of Sydney School of Medicine, Sydney, Australia, Bachelor of Medicine, Honors II, Medicine
1968 University of Sydney School of Medicine, Sydney, Australia, BS, Medicine Honors I, Medicine

Postgraduate Training

1976-1978 Radiotherapy Registrar, Prince of Wales Hospital, Sydney, Australia
1975 Histopathology Registrar, Prince of Wales Hospital, Sydney, Australia
1973-1974 Medical Registrar, St. Vincent’s Hospital, Sydney, Australia
1971-1972 Clinical Residency, St. Vincent’s Hospital, Sydney, Australia

Experience/Service

Academic Appointments

Associate Professor, Radiotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1992-1994
Associate Professor, Radiotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1988-1992
Assistant Professor, The University of Texas M. D. Anderson Cancer Center And Tumor Institute, Houston, TX, 1987-1988
Assistant Radiotherapist, Radiotherapy, The University of Texas M.D. Anderson Cancer Center and Tumor Institute, Houston, TX, 1984-1987
Assistant Professor, University of Rochester, Rochester, NY, 1980-1983
Senior Instructor, University of Rochester, Rochester, NY, 1979-1980

Other Appointments/Responsibilities

AJCC Task Force on Testis Cancer, 1994
Urologic Oncology Resource Consultant, Legislative Task Force on Cancer in Texas, Houston, TX, 1986-1994

Institutional Committee Activities

Alternate Member, Medical Practice Subcommittee, M.D. Anderson Cancer Center, 1994-present
Member, Conduct of Care Committee, M.D. Anderson Cancer Center, Houston, TX, 1989-1991
Member, Committee on Continuing Medical Education (CME), M.D. Anderson Cancer Center, Houston, TX, 1989-1990
Member, Medical Practice Subcommittee, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1987-1994
Member, Quality Assurance Committee - Department of Clinical Radiotherapy, The University of Texas System M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1986-1991
Program Director, Radiotherapy Residency Training Program, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1986-1989
Member, Ambulatory Quality Assurance Committee, The University of Texas System Cancer Center M.D. Anderson Hospital Tumor Institute, Houston, TX, 1986-1988
Member, Radiotherapy Residency Training Committee, The University of Texas M.D. Anderson Cancer Center, 1985-1992
Alternate Member, Investigational Drug Pharmacy Therapeutics Committee, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute, Houston, TX, 1984-1985
Quality Control Officer, Quality Control Officer of the Eastern Cooperative Oncology Group (ECOG) Radiation Therapy Quality Control Office, Quality control of cooperative group radiation therapy treatment, University of Rochester, Rochester, NY, 1980-1983

Selected Publications

Peer-Reviewed Original Research Articles

1. Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, Mansfield PF, Ross MI, Zagars GK. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. e-Pub 9/2009.
2. Guadagnolo BA, Zagars GK, Ballo MT, Strom SS, Pollock RE, Benjamin RS. Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer 113((2)):411-417, 7/2008.
3. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 71((2)):441-447, 6/2008.
4. Guadagnolo BA, Zagars GK, Ballo MT, Patel RS, Lewis Vao, Benjamin RS, Pollock RE. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 70((3)):760-765, 3/2008.
5. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS, Pollock RE. Evolving patterns of desmoid tumor care. J Clin Oncol 25(3):1785-1791, 2007.
6. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Pisters PWT, Benjamin RS, Pollock RE. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 69(4):1173-1180, 2007.
7. Pisters PWT, Pollock RE, Yasko AW, Lewis VO, Cormier JN, Respondek PM, Feig BW, Hunt KK, Lin PP, Zagars G, Wei C, Ballo MT. Long-term results of a prospective trial of surgery alone with selective use of radiation treatment for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 246(4):675-682, 2007.
8. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 67:158-163, 2007. PMID: 17084545.
9. Lin PP. Diaz Pino E, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PWT, Pollock RE, Lewis VO, Zagars GK, Yasko AW. The periosteal margin in soft tissue sarcoma. Cancer 109:568-602, 2007.
10. Torres MA, Ballo MT, Butler CE, Feig BW, Cormier JN, Lewis VO, Pollock RE, Pisters PWT, Zagars GK. Treatment for isolated local recurrence of soft tissue sarcoma arising in a previously irradiated field. Int J Radiat Oncol Biol Phys 67(4):1124-1129, 2007.
11. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64:106-113, 2006. PMID: 16182463.
12. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys 64(1):106-13, 2006. PMID: 16182463.
13. Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer 107:2455-2461, 2006. PMID: 17036354.
14. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PW. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol 13:1209-1215, 2006. PMID: 16952046.
15. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol 11:1079-1094, 2004. PMID: 15576833.
16. Ballo MT, Zagars GK, Cormier JN, Hunt KK, Feig BW, Patel SR, Pisters PW. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys 58:1461-1467, 2004. PMID: 15050324.
17. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 22:640-647, 2004. PMID: 14726503.
18. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 22:3375-3380, 2004. PMID: 15310783.
19. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang K. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97:1789-1796, 2003. PMID: 12655537.
20. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97:1630-1638, 2003. PMID: 12655519.
21. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol 21:3092-3097, 2003. PMID: 12915599.
22. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 56:482-488, 2003. PMID: 12738324.
23. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57:739-747, 2003. PMID: 14529779.
24. Zagars, GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS, Evans HL. Prognostic factors for localized soft tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1,225 patients. Cancer 97:2530-2543, 2003.
25. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology 62:707-713, 2003. PMID: 14550448.
26. Caudell JJ, Ballo MT, Zagars GK, Lewis VO, Weber KL, Lin PP, Marco RA, El-Naggar AK, Benjamin RS, Yasko AW. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 57:158-165, 2003. PMID: 12909228.
27. Zagars GK, Ballo MT. Sequencing radiotherapy for soft tissue sarcoma when re-resection is planned. Int J Radiat Oncol Biol Phys 56:21-27, 2003. PMID: 12694820.
28. Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys 56:473-481, 2003. PMID: 12738323.
29. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 97:2544-53, 2003. PMID: 12733154.
30. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 52:964-972, 2002. PMID: 11958890.
31. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, Garden AS, Benjamin RS. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 95:377-388, 2002. PMID: 12124838.
32. Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20:521-527, 2002. PMID: 11786582.
33. Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60:22, 2002. PMID: 12231041.
34. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, Pollack A. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8:1148-1154, 2002. PMID: 12006531.
35. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen,, II. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54:677-685, 2002. PMID: 12377318.
36. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1125, 2002. PMID: 12128107.
37. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 20:4555-4558, 2002. PMID: 12454112.
38. Lin PP, Guzel VB, Pisters PW, Zagars GK, Weber KL, Feig BW, Pollock RE, Yasko AW. Surgical management of soft tissue sarcomas of the hand and foot. Cancer 95:852-861, 2002. PMID: 12209730.
39. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58:233-239, 2001. PMID: 11489709.
40. Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer 92:1550-1555, 2001. PMID: 11745234.
41. Callister MD, Ballo MT, Pisters PW, Patel SR, Feig BW, Pollock RE, Benjamin RS, Zagars GK. Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 51:384-391, 2001. PMID: 11567812.
42. Zagars GK, Pollack A. Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51:643-649, 2001. PMID: 11597804.
43. Ballo MT, Zagars GK, Pisters PW, Feig BW, Patel SR, von Eschenbach AC. Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol 166:1306-1310, 2001. PMID: 11547063.
44. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635-642, 2000. PMID: 11020558.
45. May CA, Tamaki K, Neumann R, Wilson G, Zagars G, Pollack A, Dubrova YE, Jeffreys AJ, Meistrich ML. Minisatellite mutation frequency in human sperm following radiotherapy. Mutat Res 453:67-75, 2000. PMID: 11006413.
46. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911, 2000. PMID: 11099319.
47. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, Hunt KK. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89:1502-1511, 2000. PMID: 11013364.
48. Kelly JF; Pollack A1; Zagars GK. Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease - prognostic variables and outcome. Urologic Oncology: Seminars and Original Investigations 5:78-84, 2000.
49. Pollack A, Ashoori F, Sikes C, Joon DL, von Eschenbach AC, Zagars GK, Meistrich ML. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys 46:153-158, 2000. PMID: 10656387.
50. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 44:809-819, 1999. PMID: 10386637.
51. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17:158-167, 1999. PMID: 10458229.
52. Hanus MC, Zagars GK, Pollack A. Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 43:379-83, 1999. PMID: 10030265.
53. Hanus MC, Zagars GK, Smith LG, Pollack A. Family history in prostate cancer: Outcome analysis of hereditary versus familial prostate cancer following definitive radiation therapy. Int J Radiat Oncol Biol Phys 45:343-383, 1999.
54. Fleming JB, Berman RS, Cheng SC, Chen NP, Hunt KK, Feig BW, Respondek PM, Yasko AW, Pollack A, Patel SR, Burgess MA, Papadopoulos NE, Plager C, Zagars G, Benjamin RS, Pollock RE, Pisters PW. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 17:2772-2780, 1999. PMID: 10561352.
55. Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41:166-172, 1999. PMID: 10517874.
56. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eschenbach AC, Geara FB. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 85:1577-1585, 1999. PMID: 10193949.
57. Chaney AW, Pollack A, McNeese MD, Zagars GK. Adjuvant radiotherapy for phyllodes tumor of breast. Radiat Oncol Investig 6:264-267, 1998. PMID: 9885942.
58. Pollack A, Zagars GK. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 51:258-264, 1998. PMID: 9495708.
59. Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 51:991-997, 1998. PMID: 9609638.
60. Pollack A, Zagars GK, Goswitz MS, Pollock RA, Feig BW, Pisters PW. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys 42:563-572, 1998. PMID: 9806516.
61. Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 42:517-523, 1998. PMID: 9806509.
62. Antolak JA, Rosen,, II, Childress CH, Zagars GK, Pollack A. Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42:661-672, 1998. PMID: 9806528.
63. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 42:1007-1014, 1998. PMID: 9869223.
64. Liebross RH, Pollack A, Lankford SP, von Eschenbach AC, Zagars GK. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy. Urology 52:647-652, 1998. PMID: 9763087.
65. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 40:823-827, 1998. PMID: 9531366.
66. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 3:1823-1829, 1997. PMID: 9815569.
67. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39:1011-1018, 1997. PMID: 9392538.
68. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997. PMID: 9380819.
69. Zagars GK, Pollack A, von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80:764-775, 1997. PMID: 9264361.
70. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79:1370-1380, 1997. PMID: 9083160.
71. Lankford SP, Pollack A, Zagars GK. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy. Int J Radiat Oncol Biol Phys 38:327-333, 1997. PMID: 9226319.
72. Pollack A, Joon DL, Wu CS, Sikes C, Hasegawa M, Terry NH, White RA, Zagars GK, Meistrich ML. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res 57:2493-2500, 1997. PMID: 9192831.
73. Pollack A, Czerniak B, Zagars GK, Hu SX, Wu CS, Dinney CP, Chyle V, Benedict WF. Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 39:687-695, 1997. PMID: 9336151.
74. Zagars GK, Pollack A. Serum testosterone levels after external beam radiation for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 39:85-89, 1997. PMID: 9300743.
75. Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327-334, 1997. PMID: 9123693.
76. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 37:41-49, 1997. PMID: 9054875.
77. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagars GK, Meistrich ML, Pollack A. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38:1071-1077, 1997. PMID: 9276374.
78. Pollack A, Troncoso P, Zagars GK, von Eschenbach AC, Mak AC, Wu CS, Terry NH. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation. Prostate 31:21-28, 1997. PMID: 9108882.
79. Chyle V, Pollack A, Czerniak B, Stephens LC, Zagars GK, Terry NH, Meyn RE. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 35:281-287, 1996. PMID: 8635934.
80. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen,, II. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34:555-564, 1996. PMID: 8621278.
81. Chyle V, Zagars GK, Wheeler JA, Wharton JT, Delclos L. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 35:891-905, 1996. PMID: 8751398.
82. Zagars GK, Goswitz MS, Pollack A. Liposarcoma: outcome and prognostic factors following conservation surgery and radiation therapy. Int J Radiat Oncol Biol Phys 36:311-319, 1996. PMID: 8892453.
83. Zagars GK, Mullen JR, Pollack A. Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 34:983-994, 1996. PMID: 8600111.
84. Wu CS, Pollack A, Czerniak B, Chyle V, Zagars GK, Dinney CP, Hu SX, Benedict WF. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47:305-310, 1996. PMID: 8633392.
85. Pollack A, Lankford S, Zagars GK, Babaian RJ. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer 77:1515-1523, 1996. PMID: 8608537.
86. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475, 1995. PMID: 7879337.
87. Sands ME, Pollack A, Zagars GK. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 31:13-19, 1995. PMID: 7527796.
88. Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32:331-340, 1995. PMID: 7751174.
89. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33:23-35, 1995. PMID: 7543892.
90. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306, 1995. PMID: 7538498.
91. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 45:476-483, 1995. PMID: 7533459.
92. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 32:13-20, 1995. PMID: 7536720.
93. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33:907-912, 1995. PMID: 7591901.
94. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 31:237-245, 1995. PMID: 7836075.
95. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 153:2059-2064, 1995. PMID: 7500458.
96. Zagars GK, Kavadi VS, Pollack A, von Eschenbach AC, Sands ME. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M? Int J Radiat Oncol Biol Phys 32:21-32, 1995. PMID: 7536722.
97. Dimopoulos MA, Yau JC, Huan SD, Jagannath S, Spitzer G, Spinolo JA, Zagars GK, LeMaistre CF, Dicke KA, Zander AR. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. Am J Hematol 46:82-86, 1994. PMID: 8172200.
98. Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 151:1330-1333, 1994. PMID: 7512663.
99. Geara FB, Zagars GK, Pollack A. Influence of initial presentation on treatment outcome of clinically localized prostate cancer treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys 30:331-337, 1994. PMID: 7523344.
100. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 30:267-277, 1994. PMID: 7928456.
101. Pollack A, Zagars GK, el-Naggar AK, Gauwitz MD, Terry NH. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy. Cancer 73:1895-1903, 1994. PMID: 7511039.
102. Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 74:2819-2827, 1994. PMID: 7954243.
103. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 152:1786-1791, 1994. PMID: 7523725.
104. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:670-680, 1994. PMID: 7518341.
105. Pollack A, Zagars GK, el-Naggar AK, Terry NH. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44:711-718, 1994. PMID: 7526527.
106. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 30:279-287, 1994. PMID: 7523340.
107. Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer. Urology 44:215-220, 1994. PMID: 7519381.
108. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44:869-875, 1994. PMID: 7527168.
109. Mullen JR, Zagars GK. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 33:23-30, 1994. PMID: 7878206.
110. Gauwitz MD, Pollack A, el-Naggar AK, Terry NH, von Eschenbach AC, Zagars GK. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 28:821-828, 1994. PMID: 8138434.
111. Zagars GK, Pollack A. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment. Radiother Oncol 30:121-127, 1994. PMID: 7514308.
112. Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer 73:1904-1912, 1994. PMID: 7511040.
113. Shipley WU, Zietman AL, Hanks GE, Coen JJ, Caplan RJ, Won M, Zagars GK, Asbell SO. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 152:1799-1805, 1994. PMID: 7933239.
114. Wheeler JA, Zagars GK, Ayala AG. Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer 71:3783-3787, 1993. PMID: 8490929.
115. Dosmann MA, Zagars GK. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26:381-390, 1993. PMID: 7685748.
116. Garden AS, Zagars GK, Delclos L. Primary carcinoma of the female urethra. Results of radiation therapy. Cancer 71:3102-3108, 1993. PMID: 8490839.
117. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 72:1709-1725, 1993. PMID: 7688659.
118. Zagars GK, von Eschenbach AC. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72:538-548, 1993. PMID: 7686443.
119. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832-842, 1993. PMID: 7687516.
120. Zagars GK. The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 27:39-45, 1993. PMID: 7690017.
121. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 23(1):47-53, 1992. PMID: 1374065.
122. Gauwitz MD, Zagars GK. Treatment of seminoma arising in cryptorchid testes. Int J Radiat Oncol Biol Phys 24:153-159, 1992. PMID: 1355081.
123. Greskovich FJ, Zagars GK, Sherman NE, Johnson DE. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol 146:798-802, 1991. PMID: 1908530.
124. Zagars GK, Sherman NE, Babaian RJ. Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer 67:412-420, 1991. PMID: 1702349.
125. Zagars GK, von Eschenbach AC, Ayala AG, Schultheiss TE, Sherman NE. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 68:2370-2377, 1991. PMID: 1933773.
126. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 76:1860-1866, 1990. PMID: 2224133.
127. Talbert ML, Zagars GK, Sherman NE, Romsdahl MM. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer 66:2482-2491, 1990. PMID: 2249188.
128. Sherman NE, Romsdahl M, Evans H, Zagars G, Oswald MJ. Desmoid tumors: a 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys 19:37-40, 1990. PMID: 2380093.
129. Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G, et al. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 5:269-272, 1990. PMID: 2337738.
130. Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol 143(1):37-40, 1990. PMID: 2294257.
131. Babaian RJ, Zagars GK, Ayala AG. Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival. Semin Urol 8:225-231, 1990. PMID: 2284529.
132. Carlton JC, Zagars GK, Oswald MJ. The role of serum prostatic acid phosphatase in the management of adenocarcinoma of the prostate with radiotherapy. Int J Radiat Oncol Biol Phys 19:1383-1388, 1990. PMID: 2262362.
133. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14:1085-1091, 1988. PMID: 3133327.
134. Babaian RJ, Zagars GK. Testicular seminoma: the M. D. Anderson experience. An analysis of pathological and patient characteristics, and treatment recommendations. J Urol 139:311-314, 1988. PMID: 3339730.
135. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 14:701-709, 1988. PMID: 3350725.
136. Barkley HT, Jr, Martin RG, Romsdahl MM, Lindberg R, Zagars GK. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 14:693-699, 1988. PMID: 3350724.
137. Schultheiss TE, Zagars GK, Peters LJ. An explanatory hypothesis for early- and late-effect parameter values in the LQ model. Radiother Oncol 9:241-248, 1987. PMID: 3628858.
138. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869-872, 1987. PMID: 3304465.
139. Zagars GK, Schultheiss TE, Peters LJ. Inter-tumor heterogeneity and radiation dose-control curves. Radiother Oncol 8:353-362, 1987. PMID: 3588999.
140. Mills MD, Fuller LM, Zagars GK, McNeese MD. Spinal cord dose reduction using an anterior 13 MeV electron field situated between a split anterior 60Co supraclavicular field. Int J Radiat Oncol Biol Phys 13:1571-1575, 1987. PMID: 3114183.
141. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 60:1489-1499, 1987. PMID: 3113715.
142. Zagars GK, Babaian RJ. Stage I testicular seminoma: rationale for postorchiectomy radiation therapy. Int J Radiat Oncol Biol Phys 13:155-162, 1987. PMID: 3818383.
143. Zagars GK, Babaian RJ. The role of radiation in stage II testicular seminoma. Int J Radiat Oncol Biol Phys 13:163-170, 1987. PMID: 3818384.
144. Spitzer G, Jagannath S, Dicke KA, Armitage J, Zander AR, Vellekoop L, Horwitz L, Cabanillas F, Zagars GK, Velasquez WS. High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies. Eur J Cancer Clin Oncol 22:677-684, 1986. PMID: 3527715.
145. Rubin P, Zagars G, Chuang C, Thomas EM. Hodgkin's disease: is there a price for successful treatment? A 25-year experience. Int J Radiat Oncol Biol Phys 12:153-166, 1986. PMID: 3949565.
146. Vellekoop L, Zander AR, Kantarjian HM, Jagannath S, Hester JP, Trujillo J, McCredie KB, Zagars G, Spitzer G, Dicke KA. Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol 4:906-911, 1986. PMID: 3519881.
147. Constine LS, Zagars G, Rubin P, Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 12:1505-1508, 1986. PMID: 2428794.
148. Zagars G, Rubin P. Hodgkin's disease stages IA and IIA. A long-term follow-up study on the gains achieved by modern therapy. Cancer 56:1905-1912, 1985. PMID: 4027927.
149. Zagars G, Rubin P. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease. Cancer 56:864-873, 1985. PMID: 4016677.
150. Zagars G, Salazar OM, Baird M, Phillips TL, Rubin P. Misonidazole and hemibody irradiation in the palliation of widespread metastases. Final report of an RTOG study. Am J Clin Oncol 8:293-297, 1985. PMID: 3909800.
151. Rubin P, Salazar O, Zagars G, Constine LS, Keys H, Poulter CA, Van Ess JD. Systemic hemibody irradiation for overt and occult metastases. Cancer 55:2210-2221, 1985. PMID: 2579726.
152. Graves, RG, Kooy HM, Zagars G. Peripheral dose from 10 MV x-ray beams modified by a beam spoiler. AAMD Journal 9:20-24, 1984.
153. Coleman CN, Wasserman TH, Phillips TL, Strong JM, Urtasun RC, Schwade JG, Johnson RJ, Zagars G. Initial pharmacology and toxicology of intravenous desmethylmisonidazole. Int J Radiat Oncol Biol Phys 8:371-375, 1982. PMID: 7107354.
154. Salazar OM, Rubin P, Hendrickson FR, Poulter C, Zagars G, Feldman MI, Asbell S, Doss L. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. Int J Radiat Oncol Biol Phys 7:773-781, 1981. PMID: 6169699.

Invited Articles

1. Ballo MT Zagars GK. Radiation therapy for soft tissue sarcoma. Surg Clin N Am 12:449-467, 2003.
2. Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 30:413-416, 2003.
3. Pollack A, Zagars GK, Rosen II. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Seminars Oncol 26:150-161, 1999.
4. Pollack A, Zagars GK. Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit. Seminars Radiat Oncol 8:95-106, 1998.
5. Zagars GK. Early androgen ablation and radiation therapy for unfavorable local-regional prostate cancer. Cancer Res Ther Control 7:211-215, 1998.
6. Ballo, M, Pollack A, Zagars GK. The Fiveash/Sandler article reviewed. Oncology 12:1217-1221, 1998.
7. Pollack A, Zagars GK. Radiotherapy for stage T3B transitional cell carcinoma of the bladder. Seminars Urol Oncol 14:86-95, 1996.
8. Zagars GK. Radiotherapy versus surgery for prostate cancer: An age old question. Int J Radiat Oncol Biol Phys 35:407-409, 1996.
9. Benjamin RS, Pollock RE, Zagars GK. Soft tissue sarcomas of the extremities: continuing challenges for a multidisciplinary team. Cancer Invest 13:137-138, 1995. PMID: 7834469.
10. Zagars GK. Radiotherapy for clinically localized cancer of the prostate. . The Cancer Bulletin 45:411-417, 1993.
11. Zagars GK. : Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clinics of N Amer 20(4):737-747, 1993.
12. Zagars GK. Stage I testicular seminoma following orchidectomy: To treat or not to treat? Eur J Cancer 29:1923–1924, 1993.
13. Zagars, GK, von Eschenbach AC. The management of clinically localized adenocarcinoma of the prostate: Radiotherapy vs. surgery. . The Cancer Bulletin 41:94-97, 1989.
14. Zagars GK. Seminoma with bulky abdominal disease. Int J Radiat Oncol Biol Phys 14:395-397, 1988.

Editorials

1. Zagars GK. Stage I testicular seminoma following orchidectomy: To treat or not to treat? Eur J Cancer 29:1923-1924, 1993.
2. Zagars GK. Seminoma with bulky abdominal disease. Int J Radiat Oncol Biol Phys 14:395-397, 1988.

Abstracts

1. Lee AK, Dohadwala M, Ballo M, Levy L, Zagars G. The clinical impact of location radiation therapy and the percentage of positive lymph nodes in prostate cancer patients treated with hormonal therapy. (Presented at 47th ASTRO Meeting). Int J Radiat Oncol Biol Phys 63(Suppl):S194-S195, 2005.
2. Ballo MT, Zagars GK, Lee JE, Myers JN, Diaz EM, Sturgis EM, Gershenwald JE, Ross MI, Weber RS. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease. (Presented at 46th ASTRO Meeting). Int J Radiat Oncol Biol Phys 60(Suppl1):S256-S257, 2004.
3. Ballo MT, Zagars GK, Cormier JN, Feig BW, Patel SR, Pisters PW. The length of time between surgery and post-operative radiotherapy and local control for soft tissue sarcoma. (Presented at 45th ASTRO Meeting). Int J Radiat Oncol Phys Suppl 2:S254, 2003.

Book Chapters

1. Zagars GK. Principles of combining radiation therapy and surgery. In: Radiation Oncology. Rationale, Technique, Results. Mosby: St. Louis, 97-107, 2003.
2. Ballo, MT, Zagars GK. The soft tissue. In: Radiation Oncology. Rationale, Technique, Results. Mosby: St. Louis, 884-911, 2003.
3. Zagars GK. Management of stage I seminoma: Radiotherapy. In: Testicular Cancer. Chapman & Hall Medical: London, 99-121, 1996.
4. Zagars, GK, Norante JD, Smith JL, McDonald S. Tumors of the head and neck. In: Clinical Oncology: A Multidisciplinary Approach For Physicians And Students. W.B. Saunders: Philadelphia, 319-362, 1993.
5. Greskovich, FJ, III, Zagars GK. External beam radiation therapy for stage Cadenocarcinoma of the prostate. In: Urology Annual 1992. Appleton & Lange: Norwalk, CT, 113-115, 1992.
6. Zagars GK. Management of stage I seminoma: Radiotherapy. In: Testicular Cancer, Investigation and Management. Chapman & Hall Medical: London, 83-107, 1991.
7. Zagars GK. The role of radiotherapy in advanced abdominal metastases from testicular seminoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 292-297, 1989.
8. Barkley, HT, Lindberg RD, Zagars GK. Soft tissue sarcoma. M.D. Anderson Hospital experience. In: Innovations in Radiation Oncology. Springer-Verlag: Heidelberg, 75-79, 1987.
9. Johnson, DE, Zagars GK. Testicular seminoma. In: Current Therapy in Genitourinary Surgery. B.C. Decker Inc. Philadelphia, 140-144, 1987.
10. Johnson, DE, Logothetis CJ, Zagars GK, Smith DB. Special problems posed by cancer treatments. In: Ostomy Care and the Cancer Patient. Grune & Stratton: Orlando, 121-132, 1986.
11. Zagars, G, Norante J. Head and neck tumors. In: Clinical Oncology For Medical Students and Physicians. A Multidisciplinary Approach. 6th. American Cancer Society, 230-261, 1983.
12. Bakemeier, RF, Zagars G, Cooper RA, Rubin P. The malignant lymphomas: Hodgkin's disease, non-Hodgkin’s lymphoma, multiple myeloma and macroglobulinemia. In: Clinical Oncology For Medical Students and Physicians. A Multidisciplinary Approach. American Cancer Society, 346-369, 1983.
13. Salazar, OM, Zagars G. Radiation therapy: New approaches. In: Lung Cancer I. Martinus Nijhoff: The Hague, 209-281, 1981.
14. Zagars, G, Rubin P. The role of radiation therapy in malignant lymphomas, including Hodgkin’s disease. In: Lymphomas I. Martinus Nijhoff: The Hague, 235-341, 1981.

Letters to the Editor

1. Pollack, A, Zagars GK, Antolak JA, Kuban DA, Rosen II. In response to Drs. Kagan and Schultz. Int J Radiat Oncol Biol Phys 55:1151-1152, 2003.
2. Pollack, A, Zagars GK, Antolak, J, Kuban D, Rosen I. In response to Drs. Millar and Williams. Int J Radiat Oncol Biol Phys 55:1461-1462, 2003.
3. Zagars, GK, Pollack A. In response to Dr. Daniell. Int J Radiat Oncol Biol Phys 41:974, 1998.
4. Pollack, A, Chaney A, Zagars G. Reply to Dr Powell. Radiat Oncol Invest 41:290, 1998.
5. Pollack, A, Zagars GK. Concerning prostate cancer cover story. Time, 4/1996.
6. Pollack, A, Zagars GK, Sands ME. Androgen-ablated node-positive prostate cancer: the case for radiotherapy—in response to Drs. Wiegel and Bressel. Int J Radiat Oncol Biol Phys 32:896-897, 1995.
7. Zagars, GK, Pollack A, von Eschenbach AC, Ayala AG. Gleason grade and other prognostic factors—response to Drs. Hammond and Grignon. . Int J Radiat Oncol Biol Phys 31:435, 1995.
8. Pollack, A, Zagars GK, Sands ME. Local treatment and prostate cancer—90 years later. Response to M.V. Pilepich. Int J Radiat Oncol Biol Phys 31:436, 1995.
9. Peters, LJ, Zagars GK. Neutron therapy in prostate cancer: Is the therapeutic ratio improved? Int J Radiat Oncol Biol Phys 31:204-205, 1995.
10. Zagars, GK, von Eschenbach AC, Johnson DE. Radiotherapy versus surgery for stage C prostate cancer. Urology 41:605, 1993.
11. Zagars GK. Response to editorial by Dr. Gillian Thomas. . Int J Radiat Oncol Biol Phys 26:549, 1993.
12. Zagars, GK, von Eschenbach AC, Johnson DE. The influence of pelvic node irradiation on prognosis. Int J Radiat Oncol Biol Phys 16:882, 1989.
13. Schultheiss, TE, Zagars GK, Peters LJ. Reply to A/B ratio and the cycling status of tissue target cells. Radiother & Oncol 12:85, 1988.

Last updated: 8/13/2013